Ultragenyx Pharmaceutical's total assets for Q2 2025 were $1.31B, a decrease of -0.43% from the previous quarter. RARE total liabilities were $1.15B for the fiscal quarter, a -1.09% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.